Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Taysha Gene Therapies, Inc. TSHA
$0.68
-$0.03 (-4.09%)
На 18:03, 12 мая 2023
+4 042.65%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
45297256.00000000
-
week52high
5.09
-
week52low
0.61
-
Revenue
2502000
-
P/E TTM
0
-
Beta
1.16854700
-
EPS
-4.02000000
-
Last Dividend
0.00000000
-
Next Earnings Date
15 мая 2023 г. в 12:30
Описание компании
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN1 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 foe the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments. The company was incorporated in 2019 and is based in Dallas, Texas.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Wedbush | Outperform | Outperform | 12 авг 2022 г. |
| Chardan Capital | Buy | Buy | 12 авг 2022 г. |
| Goldman Sachs | Buy | Buy | 24 мая 2022 г. |
| Needham | Buy | Buy | 17 мая 2022 г. |
| Truist Securities | Buy | Buy | 01 апр 2022 г. |
| Baird | Outperform | Outperform | 26 окт 2022 г. |
| Needham | Buy | Buy | 25 окт 2022 г. |
| JMP Securities | Market Outperform | Market Outperform | 10 ноя 2022 г. |
| Needham | Buy | Buy | 09 ноя 2022 г. |
| Goldman Sachs | Neutral | Buy | 09 ноя 2022 г. |
| Chardan Capital | Buy | Buy | 09 ноя 2022 г. |
| Wells Fargo | Overweight | Overweight | 04 янв 2023 г. |
| JMP Securities | Market Outperform | Market Outperform | 19 янв 2023 г. |
| BTIG | Neutral | Buy | 02 февр 2023 г. |
| Truist Securities | Buy | Buy | 01 февр 2023 г. |
| Chardan Capital | Buy | Buy | 01 февр 2023 г. |
| Canaccord Genuity | Buy | Buy | 01 февр 2023 г. |
| Morgan Stanley | Equal-Weight | Overweight | 27 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Nagendran Sukumar | A | 790093 | 790093 | 30 дек 2022 г. |
| Nolan Sean P. | A | 1106131 | 1106131 | 30 дек 2022 г. |
| Session R.A. II | A | 199500 | 199500 | 10 ноя 2022 г. |
| Manning Paul B | A | 1642202 | 1500000 | 31 окт 2022 г. |
| Alam Kamran | D | 266121 | 3325 | 23 авг 2022 г. |
| Alam Kamran | D | 269446 | 9717 | 22 авг 2022 г. |
| Alam Kamran | D | 279163 | 11482 | 19 авг 2022 г. |
| Alam Kamran | D | 290645 | 7476 | 18 авг 2022 г. |
| PRASAD SUYASH | D | 530589 | 8956 | 06 июл 2022 г. |
| PRASAD SUYASH | D | 539545 | 3905 | 05 июл 2022 г. |
Новостная лента
Taysha: The FDA Just Stuck A Major Blow To Their Plans
Seeking Alpha
06 февр 2023 г. в 08:00
Taysha has a good chance of scoring with the GAN indication. Astellas may license this program if that happens.
Best Penny Stocks To Buy Now? 5 Biotech Stocks To Watch This Week
PennyStocks
21 ноя 2022 г. в 12:59
Biotech penny stocks to watch this week. Are they a buy now?
Taysha Gene Therapies: Astellas Throws Lifeline For First Dibs On Rett And GAN Programs
Seeking Alpha
17 ноя 2022 г. в 18:04
Shares have fallen by 85% since Sept 2020 IPO as cash resources dwindled to $34M as of last month. Company was forced to cut 35% of workforce, stop construction of its cGMP manufacturing facility and focus on two lead clinical candidates.
Taysha Gene Therapies, Inc. (TSHA) Q3 2022 Results - Earnings Call Transcript
Seeking Alpha
13 ноя 2022 г. в 10:40
Taysha Gene Therapies, Inc. (NASDAQ:TSHA ) Q3 2022 Results Earnings Conference Call November 8, 2022 8:00 AM ET Company Participants Kimberly Lee - Chief Corporate Affairs Officer RA Session - President, Founder and Chief Executive Officer Suyash Prasad - Chief Medical Officer and Head of Research and Development Kamran Alam - Chief Financial Officer Fred Porter - Chief Technical Officer Conference Call Participants Gil Blum - Needham & Company, LLC Geulah Livshits - Chardan Mehdi Goudarzi - Truist Securities Michael Ulz - Morgan Stanley David Hoang - SMBC Nikko Benjamin Paluch - Robert W. Baird Yanan Zhu - Wells Fargo Tiffany Marchell - William Blair Whitney Ijem - Canaccord Genuity Operator Thank you for standing by.
5 Penny Stocks To Buy According To Analysts, Targets Up To 995%
PennyStocks
08 ноя 2022 г. в 14:21
Analysts say these are penny stocks to buy. Do you agree?